CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
临床试验入组差异——聚焦 CAR-T 与双特异性抗体治疗
英文原题：Disparities in Clinical Trial Enrollment- Focus on CAR-T and Bispecific Antibody Therapies.
查看英文原题
Disparities in Clinical Trial Enrollment- Focus on CAR-T and Bispecific Antibody Therapies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
近期研究显示，持续存在的差异阻碍临床试验入组、治疗公平分配，并影响试验结果的普适性，从而损害不同人群的健康结局。本综述旨在考察临床试验入组中持续存在的差异，尤其聚焦淋巴系统恶性肿瘤、CAR-T 细胞疗法和双特异性抗体疗法。 近期发现：有针对性的干预可增加临床试验中代表不足群体的招募，并解决妨碍参与的复杂障碍；这对于实现医疗服务可及性和治疗结局公平至关重要。改进措施必须多方面开展，解决造成代表不足的社会经济、地理和生物学因素，包括放宽入组标准、改善宣传和教育，以及利用技术使试验参与者构成更多元化。
展开英文摘要原文
PURPOSE OF REVIEW: Recent studies show that unresolved disparities hinder enrollment to clinical trials, equitable distribution of treatments, and impact the generalizability of trials, compromising health outcomes across different populations. This review aims to examine the persistent disparities noted in clinical trial enrollment, with particular focus on lymphoid malignancies, CAR-T cell and bispecific antibody therapies.
RECENT FINDINGS: Targeted interventions can enhance recruitment of underrepresented groups in clinical trials and address the complex barriers hindering participation, which are essential for achieving healthcare access equity and treatment outcomes. Improvement must be multifaceted, addressing socioeconomic, geographic, and biologic factors contributing to underrepresentation. This includes more lenient eligibility criteria, improving outreach and education, as well as using technology to diversify trial participation.
论文信息
- 作者
- Islam N、Budvytyte L、Khera N、Hilal T
- 第一作者单位
- Mayo Clinic Alix School of Medicine, Scottsdale, AZ, 85254, USA.United States
- 通讯作者单位
- Division of Hematology/Oncology, Mayo Clinic, 5777 E. Mayo Blvd, Phoenix, AZ, 85054, USA. hilal.talal@mayo.edu.United States
- 文献类型
- 综述
- 期刊
- Current hematologic malignancy reports2024 Dec 4
- 原文标识
- PubMed 39630328 · DOI 10.1007/s11899-024-00747-6
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →